GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioGaia AB (OSTO:BIOG B) » Definitions » EV-to-FCF

BioGaia AB (OSTO:BIOG B) EV-to-FCF : 26.36 (As of May. 02, 2024)


View and export this data going back to 1998. Start your Free Trial

What is BioGaia AB EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, BioGaia AB's Enterprise Value is kr9,887 Mil. BioGaia AB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was kr375 Mil. Therefore, BioGaia AB's EV-to-FCF for today is 26.36.

The historical rank and industry rank for BioGaia AB's EV-to-FCF or its related term are showing as below:

OSTO:BIOG B' s EV-to-FCF Range Over the Past 10 Years
Min: -418.87   Med: 39.44   Max: 159.18
Current: 27.25

During the past 13 years, the highest EV-to-FCF of BioGaia AB was 159.18. The lowest was -418.87. And the median was 39.44.

OSTO:BIOG B's EV-to-FCF is ranked worse than
55.71% of 508 companies
in the Drug Manufacturers industry
Industry Median: 23.135 vs OSTO:BIOG B: 27.25

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-02), BioGaia AB's stock price is kr113.20. BioGaia AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was kr3.630. Therefore, BioGaia AB's PE Ratio for today is 31.18.


BioGaia AB EV-to-FCF Historical Data

The historical data trend for BioGaia AB's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioGaia AB EV-to-FCF Chart

BioGaia AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 65.69 45.75 41.71 23.11 23.00

BioGaia AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.11 24.77 33.21 24.30 23.00

Competitive Comparison of BioGaia AB's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioGaia AB's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where BioGaia AB's EV-to-FCF falls into.



BioGaia AB EV-to-FCF Calculation

BioGaia AB's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=9887.005/375.03
=26.36

BioGaia AB's current Enterprise Value is kr9,887 Mil.
BioGaia AB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr375 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioGaia AB  (OSTO:BIOG B) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

BioGaia AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=113.20/3.630
=31.18

BioGaia AB's share price for today is kr113.20.
BioGaia AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr3.630.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


BioGaia AB EV-to-FCF Related Terms

Thank you for viewing the detailed overview of BioGaia AB's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


BioGaia AB (OSTO:BIOG B) Business Description

Traded in Other Exchanges
Address
Kungsbroplan 3A, Stockholm, SWE, SE-112 27
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions; Asia Pacific, Europe, the Middle East, Africa, and the Americas.

BioGaia AB (OSTO:BIOG B) Headlines

No Headlines